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parameters of the computer model were LV axis-ratio, EDV, and percent 
LDMFS. We compared predictions of the model to currently available ciinicel 
data in patients followed 5 years after DCM 
Months 6 12 24 36 48 60 
Actual SV 33.5 37.8 36.4 39.3 35.0 34,0 
Predicted SV 34.5 36.0 35.5 38.9 39.0 40,5 
The above data used a mean LDMFS of 15%. To achieve an augmented 
SV of 50-70 cc, LDMFS must be 20--25%, respectively. Clinically, despite 
significant reductions in NYHA functional class scores, concomitant improve- 
ments in objective parameters are not seen. The computer model explains 
this discrepancy. At an LDMFS of 15% or less, the muscle wrap under- 
goes contraction with increase in LDM tension, and predominantly provides 
structural support to the dilated, failing LV. 
Thus, we conclude that to achieve significant hemodynamic augmentation, 
in addition to NYHA functional class improvement after DCM in patients with 
dilated cardiomyopathy, an LDMFS of 20°/o or more must be attained. 
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To determine the efficacy of SRP in reducing myocardial ischemia associated 
with PTCA, 120 patients (105--  with LAD lesions) undergoing elective PTCA 
were cannulated for SRP. Two randomly assigned PTCA balloon inflations 
- -  with and without SRP - -  were performed for each patient. ECG results 
were presented in ST segment deviation, and echo results were given a 
regional wall motion score 0NMS) defined ~,s Normal (0), Hypokinesia (1), 
Akinesia (2) and Dyskinesia (3). 
Results. 92 patients completed the protocol. The coronary sinus catheteri- 
zation success rate was 85%, with a mean time to enter the coronary sinus of 
12.7 ~ 14.4 minutes. Complications: 2 cases of pedcardial effusion, treated 
with pedcardiocentesis. In 63 patients with LAD lesions who developed is- 
chemia (at least 1 mm ST change, 1 unit of WMS change or 5% ejection 
fraction (EF) change from baseline) WMS dudng SRP supported PTCA vs 
control was 1.54 ± 1.34 units vs 2.49 ± 1,39 units (P < 0.0001). The EF 
decrease from baseline was subsequently -9.0:1: 4.'P/o vs -13.2 ± 5.7% (P 
< 0.001 ). The mean ECG ST deviation for all ischemic LAD patients was 2.61 
:t: 2.73 mm with SRP vs 4.15 • 3.71 without it (p < 0.001). For 21 of these 
patients, with a mean coronary sinus pressure (CSP) above 25 mmHg, the 
ST deviation was 2.06:1:1,83 mm vs 4.59 ± 4.30 (P < 0.002). Conclusion. 
SRP support reduces the development of myocardial ischemia dunng LAD 
angioplasty, with an enhanced reduction in patients with CSP > 25 mmHg. 
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Mschanica; and hemndynamic interactions of the heart-lung-unif have been 
accused to strongly influence the performance of a left ventdcular assist 
device (LVAD). In order to investigate this interaction, we designed an exper- 
imental study in anesthetized, open chest animals, 
We performed the study in 55 dogs divided in control group (n = 5) end 5 
groups with mechanical cimulatory support (each n = 10). As assist device 
we used a pneumatic system, the Medos ® HIA-VAD ~ with its pediatric sizes 
(10-ml and 25-ml). In the control group, we induced left ventricular failure 
(LVF) with subsequent occlusions of LAD and CX followed by reperfusion. 
In the next group we supported with an LVAD dudng 90 minutes, starting 
5 minutes after CX occlusion (group II). In the next group, we added right 
ventdcular ischernla by occluding the RCA simultaneously to the CX (group 
III). Those two groups we repeated but with pre-existing acute pulmonary 
hypertension (PHT), induced by the injection of 100 pm glass beads (groups 
IV and V). Group VI was similar to group V (tell and dght ventricular failure 
and PHT), but instead ol a LVAD we used BVAD support. 
In I and V no animal survived the second repodusion period (4 hourS). In fl 
and til (no PHT), all dogs survived in stable conditions. In IV (LVF, PHT), 60% 
survived, In VI with BVAD, only 40=,o survived. In III and V, dudeg occlusion of 
the RCA, the right ventdde stopped contracting and right atrial pressure and 
mean pulmonary pressure equalized. This lead to a significant drop in inflow 
on the left heart side, which still provided sufficient LVAD performance in case 
of absent PHT (111) and lead to death due to "low LVAD output" syndrome 
in V. This "low LVAO Output" syndrome couk:l be partly overcome by BVAD 
support. 
We conclude that RVF and PHT signilicantly influErce LVAD performance 
and can eventually lead to "low LVAD output" syndrome, 
Chronic Ischemi¢ Heart Disease: Clinical 
Trials 
Tuesday, March 26, 1996, 4:00 pro.--5:30 p.m. 
Orange County Convention Center, Room 209 
4:00 
~ Reduced Serum Paraoxonass Activity Is Associated 
With Progression of Atherosclerosls and New 
Clinical Events: Be~flbrate Coronary 
Atherosclerr, sls Intervention Trial 
Jan Regn~trum, Jan Nilsson, Poter Yhtp, Bojen Cercek, Ulf de Felre, 
CarI-Goran Ericson, Sanjay Kaul, Andem Hamsten, Pred]man K. Shah. 
Cedars-Sinai Medical Center, Los Angeles, CA: Karuliaska Institute, 
Stockholm, SweCen 
Paraoxonase is ;)n antioxidant enzyme carded by a subfraction of HDL- 
cholesterol and may contn'but~ to antlat1~erogenic effec~ of HDL. To deter- 
mine whether parasxonase levels are related to progression of atheresclere- 
sis and clinical coronary events, serum p.~raoxonase activity and quantitative 
corur~ry angiographic findings were cemp~red at baseline and after 5 years 
in 81 patients, age < 45 years, who had an acute myccmdiel infarction and 
were randomized to bezafibrate or plec~oo. As the paraoxonase levels were 
similar in the placebo and bezafibrale treated patients at baseline (356 vs 
359 U/L) and at 5 year follow-up (378 vs 399 U/L) the groups were pooled 
for analysis: 
Median Serum Paraoxonaea (U/L) 
Baseline 5 year's 
New Clinical Events: Yes(N = 10) 273 258 
No (N=71) 356* 399" 
New Occlusion: Yes(N = 20) 329 344 
No (N =61) 356" 410" 
New Lesions: YeslN = 74) 352 375 
No (N = 7) 456 507" 
Ho(:lges Lehman test: 95% CI < 0, Yes vs No Group 
Conclusions: Reduced serum paraoxonase activity in patients with new 
cardiac events or angiegraphic evidence of atherosclerosis progression sup- 
ports an antiatherogenic rote of paraoxonese. 
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Mibefradii (Mib) is a new once daily benzimidazolyl tetraline calcium an- 
tagonist with negative chronotmpic and no negative lenotropio effects. Its 
antiischemic effect was assessed in 303 patients (20 centers in 7 ceuntdes) 
with proven coronary disease and positive (chest pain and 1 mm ST de- 
pression) exercise test (ET). Exercise and silent ischemia were evaluated by 
repeated El' and 48 hour ambulatory ECG monitoring (AEM). After wash-out 
Baseline Treatment P vs placebo 
ET.~me to STt (s) 
Placebo N = 62 
Mib 25/50 mg N=60 
Mib 50/100 mg N = 60 
Mib 100/150 m0 N=62 
Am 5/10 mg N=59 
Ischem~c episodes (48 h AEM) 
Placebo N = 30 
Mib 20/50 mg N = 35 
Mib 50/100 mg N = 34 
Mib 100/150 mg N = 34 
Am 5/10 mg N=38 
261 299 - 
268 355 0.006 
246 357 < 0.001 
263 385 < 0.001 
264 318 0.136 
5.8 5.2 - 
4.7 2-B 0.069 
5.4 1.7 < 0.001 
6.1 1.3 < 0.001 
4.5 2.3 < 0.036 
